Liverpool COVID-19 Drug Interactions

The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.

新冠疫情席卷全球，已有充分证据表明，易受新冠病毒最严重后果影响的群体为免疫系统受损者以及伴有基础合并症的患者。因此，需要接受新冠病毒治疗的患者也将同时服用其他药物，这增加了药物相互作用（DDIs）的风险。为此，利物浦药物相互作用网站团队开发了这一免费药物相互作用资源，旨在提供有关用于治疗新冠病毒的实验性药物与常用合用药之间相互作用可能性的信息。